Business Context and Reporting Period
This Form 8-K Current Report was filed by Achieve Life Sciences, Inc. on July 29, 2020. The report details a corporate action approved by stockholders on May 12, 2020, involving an amendment to the Company's Certificate of Incorporation.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a capital structure adjustment.
Material Changes
- Reverse Stock Split: The Company implemented a 1-for-20 reverse stock split of its common stock.
- Effective Date: The split became effective on July 31, 2020, with trading on a split-adjusted basis commencing on that date.
- Share Consolidation: Every 20 issued and outstanding shares were automatically combined into one share. Outstanding warrants were similarly adjusted.
- Ownership and Rights: The split does not alter any stockholder's ownership percentage, voting rights, or the par value of the common stock.
- Trading Details: The stock continues to trade on The Nasdaq Capital Market under the symbol ACHV but was assigned a new CUSIP number (004468500).
Guidance, Outlook, and Risks
The filing does not provide management commentary on future guidance, outlook, or specific risks related to the Company's operations. The primary purpose is to disclose the mechanics and timing of the reverse stock split.
Investor Verification Checklist
- Verify the new CUSIP number (004468500) for the split-adjusted shares.
- Confirm the adjustment of outstanding warrant terms to reflect the 1-for-20 ratio.
- Check the Company's subsequent filings for any financial impact or liquidity updates resulting from the capital structure change.
- Review the Certificate of Amendment (Exhibit 3.1) for specific legal language regarding the split.